Giancarlo Benelli named as head of BeiGene Europe

Sino-American biotech BeiGene (HKEX: 06160) today announced the appointment of Giancarlo Benelli as senior vice president and head of Europe, effective January 1. This appointment will enhance the company’s commitment to bring impactful medicines to more patients across Europe, said BeiGene.

“We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformative journey for us, solidifying our position as a top global oncology innovator. Giancarlo brings a wealth of experience and a proven track record in the pharmaceutical industry, which will be instrumental as we continue to grow our presence in Europe led from our office in Basel, Switzerland. His leadership and vision are a perfect fit for BeiGene, aligning with our commitment to expanding our global footprint and enhancing our capabilities in this vital region. We look forward to the positive impact his expertise will bring to our team and our work," said John Oyler, co-founder, chairman and chief executive of BeiGene, which is soon due to rename as BeOne Medicines.

Business background

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK